血管炎市场：现况分析与预测（2023-2030）

由于血管炎治疗技术不断进步，包括基因组技术的进步，预计血管炎市场在预测期内将以 3.5% 的复合年增长率强劲增长。 例如，2023年7月，罕见免疫疾病酵素技术先驱Hansa Biopharma宣布，研究者发起的抗中性粒细胞胞浆抗体相关性血管炎2期试验中的第一位患者接受了imrifidase治疗。他宣布，他已接受治疗。 其他几个因素也促进了市场的快速扩张，包括研究投资的增加、生物製剂的更多采用、人均收入的增加、医疗保健支出的扩大以及患者治疗效果的改善。 例如，根据医疗保险和医疗补助服务中心的数据，2021 年美国医疗保健费用增加了 2.7%，达到每人 12,914 美元。

依药物类型划分，市场分为生物製剂、皮质类固醇和免疫抑制剂。 由于其高效且易于获取，皮质类固醇细分市场在 2022 年占据了最高的市场份额。 此外，皮质类固醇如泼尼松和甲基泼尼松龙由于其速效特性，多年来用于治疗血管炎的消耗量不断增加。 例如，为了给 ANCA 相关血管炎患者有效的治疗，ChemoCentryx, Inc. 于 2020 年 7 月要求美国食品和药物管理局 (FDA) 减少与日常服用类固醇相关的毒性并改善患者的治疗结果。皮质类固醇的新药申请(NDA)，可改善 其他因素，例如老年人口的增加，也正在加强皮质类固醇细分市场的基础。

依疾病类型，市场分为小血管、中血管和大血管。 由于全球小血管动脉瘤病例数量不断增加，预计小血管血管炎部分在预测期内将以最高的复合年增长率增长。 这种增长得益于化学物质和杀虫剂使用量的急剧增加。 此外，老年人口的增加正在推动这一领域的成长。 例如，根据社区生活管理局的数据，2014 年，美国有 4,620 万人年龄在 65 岁或以上，预计到 2060 年将达到 9,800 万人。 因此，小血管炎病例数的增加正在推动这种模式的发展。

根据分销管道，市场分为医院药房、零售药房和网路药房。 2022年医院药局品类占市占率最高。 此外，医院提供多种报销政策，以简化持续护理的支付流程，从而促进了该细分市场的成长。 此外，随着医院和医疗中心数量的增加，世界各地血管炎的盛行率呈上升趋势，这也促进了这一领域的全球成长。 例如，根据美国医院协会的统计，到2022年，美国将有大约6,100家医院，由非营利组织以及州和地方政府营运的社区医院组成。 因此，医院药局领域在2022年仍将维持其市场主导地位。

为了更了解血管炎产业的市场实施情况，市场分为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、义大利、欧洲其他地区）、亚洲太平洋地区（中国、日本、印度及亚太地区其他地区）以及世界其他地区。 预计亚太地区在预测期内将以最高的复合年增长率成长。 有几个因素正在推动该地区的市场发展，包括血管炎盛行率上升、患者群体庞大、老年人口不断增加以及研发活动增加。 印度和中国等国家为临床研究提供了有吸引力的投资机会，预计将积极推动血管炎的研发前景。 除此之外，成年人肥胖率的增加是该细分市场的主要驱动力。 例如，世界卫生组织（WHO）估计，到2021年，东南亚有660万5岁以下儿童和五分之一的成年人超重，预计未来几年这一数字将大幅增加。 因此，鑑于亚太地区人口规模庞大，预计在预测期内将以较高的复合年增长率成长。

目录

第一章市场介绍

• 市场定义
• 主要目标
• 利害关係人
• 限制

第二章研究方法或假设

• 调查过程
• 调查方法
• 受访者简介

第三章市场总结

第 4 章执行摘要

第 5 章 COVID-19 对血管炎市场的影响

第 6 章血管炎市场收入（2020-2030 年）

第 7 章按药物类型划分的市场洞察

• 生物製剂
• 皮质类固醇
• 免疫抑制剂

第 8 章按疾病类型划分的市场洞察

• 小血管
• 中型血管
• 伟大的船隻

第 9 章按通路划分的市场洞察

• 医院药房
• 零售药局
• 网路药局

第 10 章按地区划分的市场洞察

• 北美
  • 美国
  • 加拿大
  • 北美其他地区
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 亚太地区其他地区
• 世界其他地区

第 11 章血管炎市场动态

• 市场驱动因素
• 市场挑战

第 12 章血管炎市场机会

第 13 章血管炎市场趋势

第14章需求面与供给面分析

• 需求方分析
• 供给面分析

第 15 章价值链分析

第16章竞争场景

• 竞争状况
  • 波特五力分析

第十七章公司简介

• AbbVie Inc.
• Amgen Inc.
• Amneal Pharmaceuticals, LLC.
• F. Hoffmann-La Roche Ltd
• GSK plc.
• InflaRx GmbH
• Novartis AG
• Pfizer Inc.
• Staidson Biopharma Inc.
• Teva Pharmaceutical Industries Ltd.

第十八章免责声明

Vasculitis is a condition where blood vessels including veins, capillaries, and arteries undergo inflammation which causes them to thicken decreasing the diameter of blood vessels. Vasculitis is differentiated into various groups according to the size of the blood vessels they affect. Vasculitis can lead to certain adverse side effects like blockage of blood flow, which could cause organ damage. The vasculitis market is growing at a tremendous rate owing to an increased focus on early detection and prevention, rising research and development activities, a rise in incidences of chronic diseases, advances in treatment options, and a rise in the geriatric population. For instance, in November 2021, a clinical-stage biopharmaceutical company, InflaRx N.V. announced positive results from the European Phase II IXCHANGE study of a first-in-class anti-C5a antibody, vilobelimab, in patients with ANCA-associated vasculitis (AAV).

The Vasculitis Market is expected to grow at a strong CAGR of 3.5% during the forecast period owing to the rising technological advancements for treating vasculitis including advancements in genomic technologies. For instance, in July 2023, Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, announced that the first patient was treated with imlifidase in an investigator-initiated phase 2 study in anti-neutrophil cytoplasmic antibody-associated vasculitis. Several other factors such as increased investment in research, increasing adoption of biologics, rising per capita income, expanding healthcare expenditure, and improved patient outcomes are also leading to the surge in the market. For instance, according to the Centers for Medicare & Medicaid Services, U.S. healthcare expenditure grew 2.7% in 2021, reaching USD 12,914 per capita.

Based on drug type, the market is segmented into biologics, corticosteroids, and immunosuppressants. The corticosteroids segment held the highest share in the market in the year 2022 owing to its higher effectiveness and easy availability. Also, the consumption of corticosteroids like prednisone and methylprednisolone has risen over the years for treating vasculitis because of their fasting-acting property. For instance, in July 2020 to provide effective treatment for persons with ANCA-related vasculitis, ChemoCentryx, Inc., suggested US Food and Drug Administration (FDA) to submit a new drug application (NDA) for corticosteroids which will reduce the toxicity associated with daily steroid administration, resulting in better patient outcomes. Other factors such as the rise in the geriatric population are also strengthening grounds for the corticosteroids segment in the vasculitis market.

Based on disease type, the market is segmented into small vessel vasculitis, medium vessel vasculitis, and large vessel vasculitis. The small vessel vasculitis segment is expected to grow with the highest CAGR during the forecast period owing to rising cases of small blood vessel aneurysms globally. This growth has been supported by a surge in the usage of chemicals and pesticides. Also, rising geriatric population is driving the growth of this segment. For instance, according to the Administration for Community Living, 46.2 million people in the U.S. were above the age of 65 in 2014 and are estimated to reach 98 million in number by 2060. Thus, the rising cases of small vessel vasculitis are driving the growth of this modality.

Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies category held the highest share in the market in 2022 attributed to the availability of all required medications at a place. Also, hospitals offer multiple reimbursement policies to ease the payment process for the ongoing medical treatment which facilitates the growth of this segment. Furthermore, rising number of hospitals and healthcare centers, the prevalence of vasculitis has been on the rise around the world, which has contributed to the growth of this segment globally. For instance, according to the American Hospital Association, there were about 6,100 hospitals in the U.S. in 2022, which comprised community hospitals run by non-profit organizations as well as state and local governments. Thus, the hospital pharmacies segment held dominance in the market in the year 2022.

For a better understanding of the market adoption of the vasculitis industry, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is expected to grow with the highest CAGR during the forecast period. Several factors, such as the rising prevalence of vasculitis, a large patient pool, a rising geriatric population, and rising research and development activities are driving the regional market growth. Countries such as India and China offer attractive investment opportunities for clinical research and are anticipated to positively drive research and development prospects for vasculitis. In addition to this, rising obesity among adults is a major driving factor for this segment. For instance, the World Health Organization in 2021 estimated that in Southeast Asia 6.6 million young children under 5 years and one in five adults are currently overweight, which is expected to significantly rise in upcoming years. Hence, given the large population size of APAC, it is expected to grow with a high CAGR during the forecast period.

Some of the major players operating in the market include: AbbVie Inc.; Amgen Inc.; Amneal Pharmaceuticals, LLC.; F. Hoffmann-La Roche Ltd; GSK plc.; InflaRx GmbH; Novartis AG; Pfizer Inc.; Staidson Biopharma Inc.; Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Vasculitis Market
• 2.2. Research Methodology of the Vasculitis Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE VASCULITIS MARKET

6 VASCULITIS MARKET REVENUE (USD BN), 2020-2030F

7 MARKET INSIGHTS BY DRUG TYPE

• 7.1. Biologics
• 7.2. Corticosteroids
• 7.3. Immunosuppressants

8 MARKET INSIGHTS BY DISEASE TYPE

• 8.1. Small Vessel Vasculitis
• 8.2. Medium Vessel Vasculitis
• 8.3. Large Vessel Vasculitis

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 9.1. Hospital Pharmacies
• 9.2. Retail Pharmacies
• 9.3. Online Pharmacies

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 VASCULITIS MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges

12 VASCULITIS MARKET OPPORTUNITIES

13 VASCULITIS MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porters Fiver Forces Analysis

17 COMPANY PROFILED

• 17.1. AbbVie Inc.
• 17.2. Amgen Inc.
• 17.3. Amneal Pharmaceuticals, LLC.
• 17.4. F. Hoffmann-La Roche Ltd
• 17.5. GSK plc.
• 17.6. InflaRx GmbH
• 17.7. Novartis AG
• 17.8. Pfizer Inc.
• 17.9. Staidson Biopharma Inc.
• 17.10. Teva Pharmaceutical Industries Ltd.

18 DISCLAIMER